Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. - Wikidata - wikimedia - TriplyDB

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

http://www.wikidata.org/entity/Q35575978

about

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma Anaplastic lymphoma kinase: signalling in development and disease Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues The role of the ALK receptor in cancer biology Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy ALK and ROS1 as a joint target for the treatment of lung cancer: a review Emerging importance of ALK in neuroblastoma Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase Discovery of Potent and Selective Covalent Inhibitors of JNK Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Activating mutations in ALK provide a therapeutic target in neuroblastoma.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib Development of novel ACK1/TNK2 inhibitors using a fragment-based approach Inhibitors of the anaplastic lymphoma kinase Molecular pathogenesis of peripheral neuroblastic tumors ALK and NSCLC: Targeted therapy with ALK inhibitors Advances in bioluminescence imaging of live animal models Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.A mouse model for EML4-ALK-positive lung cancer Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature.

P2860

Q21129306-1B9608C1-3847-46B4-B4DA-DDA0C39D08C5 Q21285042-C12EF6E1-C22C-4C8F-83CA-147F33C815CF Q24312329-A9B4F86C-81C1-41C1-B1C7-22FC45AD9C48 Q24595585-89F950AE-0963-4D7E-A6D5-F43541ABDC04 Q24645724-0D1BF853-F201-44E6-85D1-35F82E298F64 Q26738384-7F34EE2C-ECFA-40A4-87EA-026F7B57FB58 Q26775817-E67A115E-A749-4953-AB58-522D903A6022 Q26795555-76307379-F3F7-4945-8A09-60B5E045203F Q26851392-9E31B6B3-09E5-43D4-8266-937E5FD2D9DC Q26858819-275A4CBF-40FA-439E-9CE8-7B3AE9F15D9E Q27660495-EABD6CD1-0256-46BD-B66F-E71ADD2D29CF Q27671787-F7E1B1FA-065C-4745-8011-D47904095DA6 Q27676927-EA5DACB1-557B-4469-8B39-2708C2806734 Q27678635-1C2AB41F-2617-4B64-89A4-0D410642EF01 Q27851440-EA723B03-4EAE-45ED-AB71-A3572EEAE33C Q27851452-3D17F760-2278-458E-9F9D-0B9DD2B5CDB1 Q27851591-54B513CF-412B-41E3-A8BD-3C6DDA7A7D16 Q27851640-0EEB31B9-9E4B-44D5-A008-6D023D72021D Q27851660-00DAFC9B-8C53-4310-8D48-1781DC2AC14F Q27851672-D04CB23D-3993-4BD8-A567-2D520F2D19A8 Q27851681-242EA5FC-E803-4C4D-84A6-97BECA27A3CA Q27851710-DBF92841-FC62-4183-8170-D4B83343B60D Q27853072-A7BAE82C-DDD6-4F70-AA81-46B3455B21C6 Q28257452-9F8E59E5-5796-4EBF-B323-BB74FA82F48A Q28267124-ED6B7A9A-659A-4698-A2C6-CC3258B1C703 Q28271405-79E4F71E-91A8-4235-B451-36BB98956295 Q28393324-9A27868E-9909-4F5F-881B-DDA9C43AFA4B Q28475505-383733DB-74AF-424C-B3A3-E0A803794FA9 Q28482066-7972C630-6B4C-4BBA-BA9A-E73C969B768D Q28546245-39940361-F7BC-4790-B7FE-949312132D7D Q28547121-DA9F811E-F672-48D2-85B7-DBACF9BE7D91 Q28571575-4C82221D-06C5-41D9-9C36-2A063DF992FA Q30384542-9736E195-FEBC-4437-8935-B45C601A5293 Q30485093-CCF2600A-FA0D-4F8E-ABBD-4D9943B06A11 Q30489704-951607EF-0733-4C91-8508-E3ADCF2E9D48 Q33636098-047661F5-550C-423C-95C3-A382818ED1E3 Q33707493-52C988C0-7EC8-4B97-8AAB-68F614EA497B Q33757079-06C78C00-31A7-48D0-BC34-30D32370AEAD Q33799157-0E93C4E5-23AB-43FF-8853-729F2472AC89 Q33859852-3369109E-B164-4D1B-BD75-FE333A496264

P2860

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

http://www.wikidata.org/entity/Q35575978

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

@ast

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

@en

type

label

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

@ast

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

@en

prefLabel

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

@ast

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

@en

P1433

Q35575978-33485C7F-030B-45FD-B582-FAAFD6792DCB

P1476

Q35575978-8A5A3866-B062-4984-9153-E1E266804AA1

P2093

Q35575978-1D7FD197-2CDA-4C14-A29C-2AE3A63A1BAE

Q35575978-52D42A8E-6E28-419F-A2D5-EFE29EC290FF

Q35575978-6602C062-6725-4DC5-A8AD-5281F47E9917

Q35575978-71A9CE4B-A0FD-4FE2-AFBC-C5EC754C1C16

Q35575978-7641ED8F-03C2-4C48-9494-A7D8293BE54A

Q35575978-7A563845-B23B-4C5B-A42E-B7804653A074

Q35575978-802F02C3-F007-448A-BD37-CC50E493B556

Q35575978-967E2798-F939-49B0-8C66-78FE920E8A58

Q35575978-9F679673-2ADB-42AF-81CC-C0C142D859D0

Q35575978-CEF8B5A4-1541-49B2-85D6-0B10318EDB62

P2860

Q35575978-030FFB8B-BDA3-4B7E-BC61-AE92C0638486

Q35575978-0CEC4CA5-5DC5-411A-8212-5BDC3C06E7E5

Q35575978-1525E608-C919-4D65-8D4E-6FD750323737

Q35575978-1BC07AA8-1469-4133-9637-974B1A0BA270

Q35575978-1CA58174-A697-4C39-975D-A1BFB7CA0217

Q35575978-21DE7F5C-DC6F-47B5-B1CB-F5F47DDFC149

Q35575978-2B4E6684-C4EF-43CD-A18B-9A465D3CC7BA

Q35575978-33B6F8A3-0E9E-425F-AE56-ECB18B1439EA

Q35575978-34745546-8DB7-49EE-B4FE-9D10CD2CE1EA

Q35575978-3929C898-204F-42A5-A3EE-36394574171B

P304

Q35575978-58A57E18-7392-437A-B3C7-7B0CE763193C

P31

Q35575978-E91BB38E-5107-4897-9730-846138346A35

P356

Q35575978-5C10EB71-3CA7-4FA6-AC4F-6D64E06B583D

P407

Q35575978-49BDD183-4058-40C8-BC7E-A19D81633603

P433

Q35575978-8CE44FD3-227F-4E41-8966-E04C5B98B494

P478

Q35575978-115FC16C-0FB2-484A-AA3F-89338F67154D

P577

Q35575978-3EC1B8E0-37E6-4F9A-B450-FFAE4A750CD3

P5875

Q35575978-C379EEBD-362F-4077-926B-7680DCE2ED54

P698

Q35575978-38DBB154-3574-4399-8376-8FC85ADF3821

P932

Q35575978-768AF3C3-6F3D-4A7A-BF68-8584DB710F20

P356

PNAS.0609412103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

@en

P2093

Anna V Galkin

http://www.w3.org/2001/XMLSchema#string

Fangxian Sun

http://www.w3.org/2001/XMLSchema#string

Gang Xia

http://www.w3.org/2001/XMLSchema#string

Greg Chopiuk

http://www.w3.org/2001/XMLSchema#string

Jiqing Jiang

http://www.w3.org/2001/XMLSchema#string

Jonathan S Melnick

http://www.w3.org/2001/XMLSchema#string

Lintong Li

http://www.w3.org/2001/XMLSchema#string

Markus Warmuth

http://www.w3.org/2001/XMLSchema#string

Nanxin Li

http://www.w3.org/2001/XMLSchema#string

Nathanael S Gray

http://www.w3.org/2001/XMLSchema#string

P2860

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Crystal structure of the tyrosine kinase domain of the human insulin receptor

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamy

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

An efficient rapid system for profiling the cellular activities of molecular libraries.

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.

Anaplastic lymphoma kinase proteins and malignancy.

Translocations involving anaplastic lymphoma kinase (ALK).

P304

270-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0609412103

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6615861

http://www.w3.org/2001/XMLSchema#string

P698

17185414

http://www.w3.org/2001/XMLSchema#string

P932

1765448

http://www.w3.org/2001/XMLSchema#string